Mackenzie Financial Corp Immunity Bio, Inc. Transaction History
Mackenzie Financial Corp
- $71.6 Billion
- Q2 2025
A detailed history of Mackenzie Financial Corp transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 10,036 shares of IBRX stock, worth $24,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,036Holding current value
$24,588% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
281Shares Held
121MCall Options Held
2.49MPut Options Held
3.14M-
Vanguard Group Inc Valley Forge, PA21.8MShares$53.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$28 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC8.76MShares$21.5 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.76MShares$19 Million0.36% of portfolio
-
Jane Street Group, LLC New York, NY7.72MShares$18.9 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $981M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...